SCHEMBL12409308

SCHEMBL12409308

COc1ccc(-c2cnc3c(NCc4cccs4)nccn23)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 8/20 0.59
TTK P33981 1/20 0.59
CLK4 Q9HAZ1 4/20 0.57
LMNA P02545 2/20 0.50
MAPT P10636 2/20 0.50
MAPK1 P28482 2/20 0.50
ADORA3 P0DMS8 2/20 0.49
TP53 P04637 1/20 0.46
FLT3 P36888 1/20 0.46
HSD17B10 Q99714 2/20 0.44
DYRK1A Q13627 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
TSHR P16473 2/20 0.44
CYP2C19 P33261 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409242 0.84 TTK (0.56) FYNTTKLMNAMAPTADORA3
SCHEMBL12409314 0.83 MAPK1 (0.50) FYNTTKLMNAMAPTMAPK1
SCHEMBL3469185 0.82 TTK (0.68) FYNTTKCLK4MAPTADORA3
SCHEMBL12409279 0.82 TTK (0.70) FYNTTKADORA3FLT3CYP1A2
SCHEMBL12409234 0.82 FYN (0.54) FYNTTKCLK4LMNAMAPK1
SCHEMBL12409294 0.81 TTK (0.61) FYNTTKCLK4LMNAMAPT
SCHEMBL3467010 0.81 TTK (0.59) FYNTTKCLK4LMNAMAPT
SCHEMBL12409247 0.80 FYN (0.45) FYNTTKADORA3
SCHEMBL12409298 0.80 MAPK1 (0.48) FYNTTKCLK4MAPTMAPK1
SCHEMBL2178662 0.80 TTK (0.48) FYNTTKADORA3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 FYN 3511/4885TTK 3239/4885CLK4 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.